CoNCERT Pharmaceuticals is developing novel small molecule drugs for unmet medical needs. CoNCERT's technology represents a fundamental advance in the creation of new medicines and holds the promise of both greatly reducing R&D cycle times and enhancing the likelihood of successful clinical development. The company was founded in 2006 and is based in Lexington, MA. Flagship General Partner Doug Cole is a Board Director.

www.concertpharma.com